19.53
+1.745(+9.81%)
Currency In USD
| Previous Close | 17.78 |
| Open | 17.78 |
| Day High | 20.03 |
| Day Low | 17.74 |
| 52-Week High | 130 |
| 52-Week Low | 6.76 |
| Volume | 1.15M |
| Average Volume | 941,084 |
| Market Cap | 171.15M |
| PE | 0.07 |
| EPS | 279.15 |
| Moving Average 50 Days | 19.18 |
| Moving Average 200 Days | 26.39 |
| Change | 1.75 |
If you invested $1000 in Tonix Pharmaceuticals Holding Corp. (TNXP) 10 years ago, it would be worth $0 as of December 04, 2025 at a share price of $19.525. Whereas If you bought $1000 worth of Tonix Pharmaceuticals Holding Corp. (TNXP) shares 5 years ago, it would be worth $0.05 as of December 04, 2025 at a share price of $19.525.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder
GlobeNewswire Inc.
Nov 24, 2025 12:00 PM GMT
Tonix plans to initiate potential pivotal Phase 2 HORIZON study of TNX-102 SL in adults with major depressive disorder in mid-2026 More than 21 million US adults experience a major depressive episode each year CHATHAM, N.J., Nov. 24, 2025 (GLOBE N
Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment
GlobeNewswire Inc.
Nov 17, 2025 12:00 PM GMT
TONMYA is now available by prescription and available for pharmacy ordering nationwide TONMYA is the first FDA-approved treatment for fibromyalgia in more than 15 years TONMYA is a unique, non-opioid, once-daily bedtime analgesic that significantly r
Tonix Pharmaceuticals to Participate in the Stifel 2025 Healthcare Conference
GlobeNewswire Inc.
Nov 06, 2025 12:00 PM GMT
CHATHAM, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated commercial biotechnology company, today announced that Seth Lederman, M.D., Tonix’s Chief Executive O